Whitney P Kirschbrown (Whitney Kirschbrown)

Publication Activity (10 Years)

Years Active: 2021-2021
Publications (10 Years): 4

Top Topics

Optical Coherence Tomography

Tyrosine Kinase

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cancer chemotherapy and pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Bei Wang, Rong Deng, Stefanie Hennig, Tanja Badovinac Crnjevic, Monika Kaewphluk, Matts Kågedal, Angelica L Quartino, Sandhya Girish, Chunze Li, Whitney P Kirschbrown
Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. Cancer chemotherapy and pharmacology (2021)
Bei Wang, Rong Deng, Stefanie Hennig, Tanja Badovinac Crnjevic, Monika Kaewphluk, Matts Kågedal, Angelica L Quartino, Sandhya Girish, Chunze Li, Whitney P Kirschbrown
Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study. Cancer chemotherapy and pharmacology 88 (3) (2021)
Nancy U Lin, Mark D Pegram, Solmaz Sahebjam, Nuhad K Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Whitney P Kirschbrown, Priya Kumthekar
Reply to J. Wei et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Nancy U Lin, Mark D Pegram, Solmaz Sahebjam, Nuhad K Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Whitney P Kirschbrown, Priya Kumthekar
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (24) (2021)